An oral formulation of arginine -ketoglutarate is disclosed which formulation
is comprised of arginine -ketoglutarate and one or more excipient materials.
A wide range of different controlled release formulations will be apparent to those
skilled in the art upon reading this disclosure. The formulation of arginine -ketoglutarate
and excipient material is designed to obtain a desired result, e.g. attenuate symptoms
suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl
hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic
of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results
are obtained by increasing the period of time that a therapeutic level of arginine
-ketoglutarate is continuously maintained in the patient. The therapeutic
level as well as the period of time over which that level must be maintained can
vary between patient based on a range of factors such as the condition of the patient
and the patient's reactivity to arginine -ketoglutarate. However, the period
of time will be greater than that obtained with a conventional quick release arginine
-ketoglutarate formulation.
